Development of a novel and highly selective CDK4/6 inhibitor for treating cancer [ 2018 - 2020 ]

Research Grant

Researchers: Prof Shudong Wang (Principal investigator) ,  A/Pr Elgene Lim ,  A/Pr Robert Milne ,  Prof Wayne Tilley

Brief description We have identified and patented novel drug molecules targeting enzymes namely CDKs 4 and 6, that are important for survival of cancer cells. The drugs are highly selective and potent against CDK4/6, well absorbed orally, and have attracted much interest from a pharmaceutical company. Further detailed work is needed to characterize fully their anti-cancer effects and toxicity, thereby securing a major investment from our commercial partner for drug development for treating cancers.

Funding Amount $AUD 1,187,595.79

Funding Scheme Development Grants

Notes Development Grant